⌘K

19:03:31·19m

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

ByQuantisnow·Wall Street's wire, on your screen.

BBIO· BridgeBio Pharma Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc. | Quantisnow